CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Won the “2023 Cailian Press Zhiyuan Award – Pioneer in Corporate Governance”
2024-01-10

Won the “2023 Cailian Press Zhiyuan Award – Pioneer in Corporate Governance”

Was Selected as the “Most Popular Southbound Stock Connect Company” of 2023 Annual Golden GuruClub Awards

Was Selected as the “Most Popular Southbound Stock Connect Company” of 2023 Annual Golden GuruClub Awards

Joined Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in Southeast Asia

Joined Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in Southeast Asia

Diazepam Nasal Spray (VALTOCO) has issued its First Prescriptions

Diazepam Nasal Spray (VALTOCO) has issued its First Prescriptions

First Prescription of ILUMETRI (Tildrakizumab Injection) Has Been Issued
2023-12-18

First Prescription of ILUMETRI (Tildrakizumab Injection) Has Been Issued

Innovative drugs VALTOCO (Diazepam Nasal Spray),ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL
2023-12-13

Innovative drugs VALTOCO (Diazepam Nasal Spray),ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL

Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China
2023-12-12

Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

Won the “Most Socially Responsible Listed Company Award” by Zhitong Finance
2023-12-07

Won the “Most Socially Responsible Listed Company Award” by Zhitong Finance

New Drug Application of Methotrexate Iniection, Pre-filled Svringe (for RA) was accepted by China NMPA
2023-12-05

New Drug Application of Methotrexate Iniection, Pre-filled Svringe (for RA) was accepted by China NMPA

First Prescription of Metoject (Methotrexate Pre-filled Injection) Has Been Issued.
2023-10-30

First Prescription of Metoject (Methotrexate Pre-filled Injection) Has Been Issued.

Selected into “Top 20 Chinese pharmaceutical Listed Companies in ESG Competitiveness”
2023-10-19

Selected into “Top 20 Chinese pharmaceutical Listed Companies in ESG Competitiveness”

Shenzhen Kangzhe Listed on the “Corporate Donation List in of 2022 Shenzhen Charitable Donation List”
2023-09-25

Shenzhen Kangzhe Listed on the “Corporate Donation List in of 2022 Shenzhen Charitable Donation List”

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号